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Abstract
Background and aim: Marine n-3 fatty acids and g-linolenic acid both have anti-inflammatory effects and may be
useful to help treat inflammatory diseases. The effects of these alone or combined were examined in patients with
arthritis in a randomized controlled trial.
Design: Patients with rheumatoid arthritis or psoriatic arthritis were randomized into four groups in a double-blind,
placebo-controlled parallel designed study. Patients received the respective capsules (1: 3.0 g n-3 LC-PUFA/d; 2: 3.2
g g-linolenic acid/d; 3: 1.6 g n-3 LC-PUFA + 1.8 g g-linolenic acid/d; 4: 3.0 g olive oil) for a twelve week period.
Clinical status was evaluated and blood samples were taken at the beginning and at the end of the period.
Differences before and after intervention were tested with paired t-test or with Wilcoxon test for non-normal data
distribution.
Results: 60 patients (54 rheumatoid arthritis, 6 psoriatic arthritis) were randomised, 47 finished per protocol. In
group 1, the ratio of arachidonic acid (AA)/eicosapentaenoic acid (EPA) decreased from 6.5 ± 3.7 to 2.7 ± 2.1 in
plasma lipids and from 25.1 ± 10.1 to 7.2 ± 4.7 in erythrocyte membranes (p ≤ 0.001). There was no significant
influence on AA/EPA ratio due to interventions in group 2-4. In group 2, the intake of g-linolenic acid resulted in a
strong rise of g-linolenic acid and dihomo-g-linolenic acid concentrations in plasma lipids, cholesteryl esters, and
erythrocyte membranes. The combination of n-3 LC-PUFA and g-linolenic acid (group 3) led to an increase of
g-linolenic acid and dihomo-g-linolenic acid concentrations in plasma lipids, cholesteryl esters, and erythrocyte
mem-branes. This increase was only half of that in group 2.
Conclusions: Incorporation of eicosanoid precursor FAs was influenced by an intake of n-3 LC-PUFA and
g-linolenic acid suggesting a possible benefit for therapy of chronic inflammatory diseases.
Trial Registration: ClinicalTrials NCT01179971
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Rheumatoid arthritis (RA) is an autoimmune disease
characterised by synovial proliferation in joints as well as
infiltration of the synovial stroma by B cells, CD4+ helper
T cells, plasma cells, and macrophages [1]. The inflam-
mation in RA results in an overproduction of PGE2, cyto-
kines, and nitrogen monoxide. Tumor necrosis factor
(TNF) a and interleukin (IL)-1 are key pro-inflammatory
molecules implicated in the cytokine cascade in RA [2].
The beneficial effects of n-3 long-chain polyunsaturated
fatty acids (n-3 LC-PUFA) found in fish and fish oils on
clinical parameters of RA were demonstrated in at least
17 of 18 randomized controlled clinical trials [3]. Eico-
sapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic
a c i d( D H A ,C 2 2 : 6 n - 3 ) ,a sw e l la sn - 6P U F A ,s u c ha sa r a -
chidonic acid (AA, C20:4n-6) are present in cell phos-
hpolipids. EPA is a precursor of prostaglandins (PGs;
series-3) and leukotrienes (LTs; series-5). Supplementa-
tion with n-3 LC-PUFA results in a replacement of AA
in cell membranes [4,5]. Additionally, n-3 LC-PUFA reg-
ulate inflammatory and immunological processes by
competing with the enzymatic conversion to eicosanoids
thereby diminishing the formation of inflammatory ser-
ies-2 PGs and series-4 LTs from AA. In fact, n-3 LC-
PUFA are involved in many physiological processes
through their influence on membrane fluidity, eicosanoid
synthesis, receptor affinity, cell signalling, gene expres-
sion, cytokine production, and the production of pro-
resolving mediators [3].
g-linolenic acid (C18:2n-6, GLA) derived from plant
seed oils, e.g., borage, black current seed, and primrose
oil can be metabolized to dihomo-g-linolenic acid
(C20:3n-6; DGLA), the immediate precursor of series-1
PGs. Anti-inflammatory and immunoregulatory effects
of these eicosanoids have also been proposed. Several
clinical trials have shown that large doses of GLA
(between 1400 - 2800 mg/d) may also exhibit anti-
inflammatory properties and reduce disease activity in
patients with RA [6-13].
In the present trial, patients with RA or psoriatic
arthritis (PA) received capsules containing either n-3
LC-PUFA, GLA, or olive oil as a control. A synergistic
effect due to the combination of n-3 LC-PUFA and
GLA was also regarded in the present study. The pri-
mary outcome measure of this study was the relative
variation of the eicosanoid precursor PUFA (EPA, AA,
AA/EPA ratio, DGLA) in erythrocyte membranes (EM)
indicative of change in the production of eicosanoids.
The secondary outcome measure was the disease activity
(disease activity score DAS28, visual analog scale VAS).
We expect an increased incorporation of the supple-
mented PUFA and hypothesized that the resulting
changes on the amount of eicosanoid precursor fatty
acids influence disease activity.
Materials and methods
Subjects
Patients aged between 18 and 90 years were eligible, provid-
ing they met the revised criteria of the American College of
Rheumatology (ACR, 1987) for RA and the criteria of the
European Spondy-loarthropathy Study Group (ESSG; 14)
for PA. In addition, a least medium activity of the diseases
was required at baseline, defined by positivity for at least 2
of 5 parameters: number of tender joints ≥ 3, number of
swollen joints ≥ 3, duration of early morning stiffness
(EMS) ≥ 30 min, erythrocyte sedimentation rate (ESR) > 12
mm/h, and C-reactive protein (CRP) > 3 mg/L (Table 1).
Patients receiving nonsteroidal anti-inflammatory drugs
(NSAID) or corticosteroids or both were eligible if dosage
had been stable for at least 4 weeks on the day of inclusion
and remained below this limit throughout the study. Sub-
jects on disease-modifying antirheumatic drugs (DMARD)
should have received a constant dosage for at least 8 weeks
before and throughout the study. Subjects diagnosed with
gastrointestinal or metabolic diseases, known for alcohol
and drug abuse, taking dietary supplements (e.g., fish oil
Table 1 Baseline characteristics of the study participants
Age (yr)
Mean ± SD 56 ± 13
Range 29-88
Sex (%)
Male 8.5
Female 91.5
BMI (kg/m
2)
Mean ± SD 26 ± 6
Range 19-48
CRP (mg/dL)
Mean ± SD 7.8 ± 14.0
Range 0-75
BSG (1 h)
Mean ± SD 15.4 ± 13.1
Range 4-57
Tender joint count
Mean ± SD 9.2 ± 6.0
Range 1-26
Swollen joint count
Mean ± SD 4.1 ± 3.4
Range 0-14
DAS28
Mean ± SD 4.5 ± 0.9
Range 2-7
VAS (mm)
Mean ± SD 50 ± 20
Range 22-87
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Page 2 of 12capsules, evening primrose or borage oil), those participat-
ing in other clinical trials 4 weeks before the start of this
study, pregnant women or breastfeeding mothers, and sub-
jects with a known food allergy or food intolerance were
excluded.
Patients (resident in the surrounding area of Berlin,
Germany) fulfilling all these requirements entered the
trial after giving their written informed consent, and
were individually allocated to one of the four treatment
groups by means of receiving prefabricated sealed envel-
opes, generated by a randomization list with a block size
of 8. The number of patients as calculated by the power
analysis (PASS 6.0, Power Analysis and Sample Size,
NCSS Statistical Software, Kaysville, Utah 84037; with
repeated measurement and standard deviation) was 15
per group. Capsules were handed out in glass beakers
marked only with the patient number. Enrollment and
a s s i g n m e n tt oi n t e r v e n t i o n sw e r ed o n eo n l yb yt h et r i a l
physicians (RS, UH, MV). All personal (trial physicians,
study nurse, secretary) was blinded. Study medication
was labeled only with patient numbers and manufac-
tured outside the trial site.
Study candidates were excluded from the study at any
time after enrollment for the following rea-sons: patient’s
request, acquisition of a serious infection, inadequate con-
trol of arthritic symptoms (≥ 50% increase of the number
of swollen or tender joints), and reinstitution (change
of dosage or begin of a new therapy with DMARD), or
non-compliance. The study protocol was approved by the
Ethical Committee of Charité - University of Medicine,
Berlin, Germany.
Study design and intervention
In this randomized double-blind controlled clinical trial,
patients were randomized to 12 weeks of treatment with
one of 4 different supplements (allocation ratio 1:1:1:1):
3000 mg n-3 LC-PUFA/d (1); 3150 mg GLA/d (2);
1575 mg n-3 LC-PUFA plus 1800 mg GLA/d (3); 3000 mg
olive oil (4); (see Figure 1). Fasting blood samples were
d r a w na tt h eb e g i n n i n ga n da tt h ee n do ft h e1 2 - w e e k
study period from a cubital vein for assessment of FA dis-
tribution in plasma lipids (PL), cholesteryl esters (CE), and
EM (proportions of EPA, AA, DGLA, AA/EPA ratio in
EM: primary outcome measure) and for routine laboratory
assessment. During the visits at the beginning and at the
end of each period, a clinical evaluation was performed
consisting of the DAS28, VAS (0-100 mm), and EMS (as
estimated by the patient) (secondary outcome measure).
Patients documented their daily use of medications and the
average daily requirement from the last visit was compared
with the baseline dose. Additionally, before begin and at
the end of each study period, the patients documented
their normal nutritional habits in a Food Frequency Proto-
col (FFP) over 7 days.
Laboratory analysis
The venous blood was collected into one citrate tube,
and one evacuated tube (10 mL) containing Li-heparin
(Sarstedt
®). Plasma and platelets were seperated by
centrifugation (10 min, 500 rcf). The platelets were
washed twice with physiological NaCl solution (0.9%).
Plasma and platelets were stored at -80°C until
analysis.
Red blood cell membranes were isolated according to
Burton et al. [15]. PL and EM were extracted using a
methanol/chloroform-mixture according to Bligh and
Dyer [16]. The CE were isolated from PL extracts by thin
layer chromatography (TLC) with the use of hexane/
diethyl ether/acetic acid (85:15:0.2, v/v/v). Further, an
acid-catalyzed methylation of the PL, CE, and EM was per-
formed with anhydrous HCl/methanol (5% w/v; Supelco,
USA). The resulting fatty acid methyl esters (FAME) were
isolated by TLC by means of hexane/diethyl ether/acetic
acid (85:15:0.2, v/v/v). The FA analysis was conducted via
GC (GC-17 V3; Shimadzu, Tokyo, Japan) equipped with
an auto sampler and flame ionization detector. FAs ran-
ging from four to twenty-five carbon atoms in length were
determined, using a fused silica capillary column
(CP Select for FAME (Chrompack), 200 m × 0.25 mm ×
0.25 μm; Shimadzu, Japan, USA). FA concentrations were
expressed as percentage of the total area of all FA peaks
(% of total FAME) using GC solution. The n-3 FA index
was calculated from the sum of EPA and DHA in relation
to total FA content in EM [17].
Statistical analysis
Statistical assessment of the data was performed using
SPSS version 14.0 (SPSS Inc . ,C h i c a g o ,I L ,U S A ) .A
value of p ≤ 0.05 indicates significant intra- and inter-
group changes. The results are stated as mean ± SD.
The Kolmogorov-Smirnow-Test was used to verify the
distribution of data.
Differences before and after intervention were tested
with paired t-test or with Wilcoxon test for non-normal
data distribution. Relationships between variables were
calculated using Pearson’s correlation or Kendall-Tau, in
case of not normally distributed data.
Results
Fifty four patients with RA (49 f, 5 m), and six patients
with psoriatic arthritis (4 f, 2 m) started the trial (intent to
treat, ITT), full data after three-month of intervention
could be retrieved for 47 (per protocol, PP). For these
patients mean age was 56.2 ± 13.6 years (mean BMI 26.4
±6 . 1k g / m
2). Thirteen patients, representing a drop out
rate of 22% did not complete the study because of the fol-
lowing reasons: they claimed to experience smell and
odor, felt an insufficient relief of their symptoms, or
showed other reasons of non-compliance (Figure 2).
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Page 3 of 12Influence on disease activity
A significant decrease of DAS28 was determined due to
the daily intake of 3 g n-3 LC-PUFA (from 4.7 ± 0.9 to
3.8 ± 1.2, P ≤ 0 . 0 5 ,g r o u p1 )o r3gG L A( f r o m4 . 7±1 . 1
to 3.9 ± 0.9, group 2, P ≤ 0.05). The DAS28 was not influ-
enced due to intervention in group 3 and the intake of
olive oil revealed a trend towards a decrease of DAS28
(from 4.4 ± 0.6 to 3.7 ± 1.2, P ≤ 0.05, P ≤ 0.1; 18). The
VAS scale also decreased significantly from 61.3 ± 17.6 to
3 6 . 2±2 3 . 6m mi ng r o u p1( P≤ 0.05), and tended to
decrease from 51.9 ± 21.0 to 35.6 ± 25.0 mm in group 2
(P ≤ 0.1). The VAS scale was not influenced in group 3
(baseline: 44.2 ± 16.4 mm, end: 45.3 ± 25.0 mm) and
group 4 (baseline: 41.8 ± 21.4, end: 41.6 ± 26.0 mm; 19).
Influence of the intervention on FA distribution in plasma
lipids (PL)
Due to the intake of 3 g n-3 LC-PUFA/d (group 1),
EPA, docosapentaenoic acid (DPA, C22:5n-3), DHA, n-3
LC-PUFA and n-3 FA increased significantly (p ≤ 0.01;
Table 2). In addition, there was a significant decrease of
t h eA A / E P Ar a t i o ,a sw e l la st h en - 6 / n - 3P U F Ar a t i o
and MUFA, especially oleic acid (C18:1n9) in this group
(p ≤ 0.01; Table 2).
In the group ingesting 3 g GLA/d (group 2), the con-
centrations of linoleic acid (LA, C18:2n-6), a-linolenic
acid (ALA, C18:3n-3), EPA, DPA, n-3 LC-PUFA, n-3
PUFA and MUFA decreased significantly, whereas con-
centrations of GLA, AA, n-6 PUFA and SFA, as well as
the n-6/n-3 PUFA ratio increased significantly (p ≤ 0.05;
Table 2).
In group 3 (combination of n-3 LC-PUFA+GLA), only
GLA concentrations increased significantly (p ≤ 0.05)
whilst other FAs were not influenced significantly
(Table 2).
In the olive oil group (group 4), DPA, and n-3 LC-
PUFA decreased significantlyw h e r e a st h er a t i oo fn - 6 /
n-3 PUFA increased (p ≤ 0.05; Table 2). However, the
concentration of oleic acid (C18:1n9) was not affected.
Influence of the intervention on FA distribution in
cholesteryl esters (CE)
In group 1, the concentrations of EPA and the sum of
n-3 LC-PUFA increased, whereas ALA and GLA
3 g GLA/d
FFP                                      FFP
3g n-3 LC-PUFA/d
1.5g n-3 LC-PUFA + 
12 wks
n = 14
Control (3g olive oil/d)
3g GLA/d
1.5g GLA/d 
n = 8
n = 13
n = 12
Blood
DAS28, VAS
Blood
DAS28, VAS
DAS28 disease  activity  score 
VAS  visual analog scale
FFP Food frequency protocol (7d)
Figure 1 Intervention study design.
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Page 4 of 12decreased significantly (p ≤ 0.05). The respective
concentrations of further FAs remained unchanged
(Table 3).
Due to the consumption of GLA (group 2), the
amounts of GLA, DGLA, and AA increased signifi-
cantly, LA decreased in this group (p ≤ 0.05). No
changes were observed in group 3 and 4 regarding the
chosen FAs, except for the increase in plamitic acid
(C16:0), GLA and DGLA in group 3 (Table 3).
Influence of the intervention on FA distribution in
erythrocyte membranes (EM)
Due to the consumption of a high dosage of n-3 LC-PUFA
in group 1, oleic acid, LA, GLA, ALA, DGLA, AA, AA/
EPA, n-6 PUFA and n-6/n-3 ratio decreased significantly,
whereas for EPA, DPA, DHA, n-3 LC-PUFA, n-3 PUFA
and SFA an increase was observed (p ≤ 0.05; Table 4). The
AA/EPA ratio decreased from 25.1 ± 10.1 to 7.2 ± 4.7 (p ≤
0.001). Further, the n-3 FA index in this group increased
significantly from 3.1 ± 0.8 to 5.5 ± 1.7% FAME (p ≤
0.001), it remained unchanged in the other intervention
groups (Table 4).
Due to the intake of 3 g GLA/d (group 2), there was a
threefold increase of GLA, and DGLA was doubled in
comparison to the baseline concentrations (p ≤ 0.05).
Additionally, the proportions of ALA and MUFA
decreased significantly in this group. A notable rise in
GLA, DGLA and EPA was the result of supplementation
in group 3 (p ≤ 0.05). In the olive oil group, no effect on
the chosen FAs was observed (Table 4).
Dietary intake
The analysis of FFP provided information regarding the
basal diet without ingestion of supplementary capsules.
The data showed that the intake of food is comparable
between the four intervention groups since only mar-
ginal differences in dietary intake between start and end
FFP in group 2 (carbohydrates) and 3 were revealed
(dietary fiber, Table 5). Taken together, the intake of
energy, carbohydrates, dietary fibers, MUFA and calcium
was in accordance with the reference values, whereas
the intake of protein, fat and SFA was high and that of
PUFA was low in comparison to the guidelines ([20];
Table 5).
Assessed for eligibility
(n=96)
Randomized (n=60)
Group 1 
(3 g n-3 LC-PUFA/d)
Excluded  (n=36)
- Not meeting inclusion criteria 
(n=36)
- Declined to participate (n=0)
- Other reasons (n=0)
Discontinued intervention (give 
reasons) (n=1)
- Effort of capsules intake
Allocated to intervention (n=15)
- Received allocated intervention 
(n=15)
- Did not receive allocated 
intervention (give reasons) (n=0)
Analysed  (n=14)
- Excluded from analysis (give 
reasons) (n=0)
Allocated to intervention (n=15)
-Received allocated intervention 
(n=15)
- Did not receive allocated 
intervention (give reasons) (n=0)
Discontinued intervention (give 
reasons) (n=7)
- Effort of capsules intake (n= 4) 
- Unsavoury aftertaste after 
capsules intake (n =3)
Analysed  (n=8)
- Excluded from analysis (give 
reasons) (n=0)
Allocated to intervention (n=15)
- Received allocated intervention 
(n=15)
- Did not receive allocated 
intervention (give reasons) (n=0)
Discontinued intervention (give 
reasons) (n=2)
- Effort of capsules intake (n= 2)
Analysed  (n=13)
- Excluded from analysis (give 
reasons) (n=0)
Allocated to intervention (n=15)
- Received allocated intervention 
(n=15)
- Did not receive allocated 
intervention (give reasons) (n=0)
Discontinued intervention (give 
reasons) (n=3)
- Effort of capsules intake (n= 2) 
- Contempt against eligibility 
criteria (n=1)
Analysed  (n=12)
- Excluded from analysis (give 
reasons) (n=0)
Group 2 
(3 g GLA/d)
Group 3
(1.6 g n-3 LC-PUFA + 1.8 g GLA/d)
Group 4 
(3 g olive oil/d)
Figure 2 Flow diagram of the study participants. Ninty six patients were screened for enrollment. Of them, 60 met the inclusion criteria and were
randomized. Thirteen subjects discontinued the study and the remained 47 individuals completed the 12-weeks period of the study per protocoll.
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Page 5 of 12Additionally, patients documented their consumption
of fish or fish products during the study time in order
to record their additional intake of n-3 LC-PUFA. The
majority of patients in groups 1 and 3 consumed 2-3
portions of fish per wk whereas subjects in groups 2
and 4 ate 1-2 portions. Thus, it follows that the addi-
tional daily intake of n-3 LC-PUFA due to fish and fish
products was comparably high and varied between 0.3 g
Table 2 Fatty acid distribution in plasma lipids (PL) at baseline and after a 12 wk intake of the capsules
a,b
PL (% FAME) wks n-3 LC-PUFA
(group 1)
GLA
(group 2)
n-3 LC-PUFA + GLA
(group 3)
Control (olive oil)
(group 4)
C16:0 0 22.0 ± 1.71 22.2 ± 1.43 22.6 ± 2.08 21.9 ± 1.65
12 22.2 ± 1.64 22.9 ± 1.65* 22.9 ± 2.30 22.8 ± 2.21
C16:1 0 2.42 ± 0.82 2.02 ± 0.25 2.30 ± 0.77 2.29 ± 0.65
12 2.35 ± 0.71 1.99 ± 0.33 2.08 ± 0.72 2.25 ± 0.59
C18:0 0 6.51 ± 0.60 6.38 ± 0.25 6.78 ± 0.78 6.48 ± 0.76
12 6.62 ± 0.86 6.45 ± 0.55 7.19 ± 0.79 6.60 ± 0.59
C18:1 n9 0 20.1 ± 1.68 19.5 ± 1.87 19.1 ± 2.33 18.8 ± 2.60
12 18.1 ± 2.20** 18.2 ± 1.61 18.7 ± 1.94 19.4 ± 1.57
C18:2 n-6 0 28.2 ± 3.23 28.7 ± 3.08 26.7 ± 4.56 29.5 ± 3.93
(LA) 12 26.6 ± 3.69 26.3 ± 2.41** 25.9 ± 3.51 29.4 ± 3.54
C18:3 n-6 0 0.36 ± 0.11 0.52 ± 0.43 0.44 ± 0.28 0.33 ± 0.13
(GLA) 12 0.39 ± 0.32 1.26 ± 0.20** 0.72 ± 0.28** 0.29 ± 0.09
C18:3 n-3 0 0.65 ± 0.44 0.81 ± 0.37 0.48 ± 0.18 0.59 ± 0.34
(ALA) 12 0.42 ± 0.15 0.43 ± 0.16* 0.45 ± 0.17 0.56 ± 0.25
C20:3 n-6 0 0.25 ± 0.25 0.16 ± 0.10 0.27 ± 0.29 0.23 ± 0.31
(DGLA) 12 0.56 ± 0.98 0.88 ± 1.51 0.36 ± 0.39 0.41 ± 0.44
C20:4 n-6 0 5.18 ± 1.21 5.83 ± 1.51 6.06 ± 1.67 4.94 ± 1.14
(AA) 12 5.35 ± 1.22 7.45 ± 1.63* 6.15 ± 1.63 4.96 ± 1.25
C20:5 n-3 0 1.16 ± 0.86 1.05 ± 0.50 1.56 ± 1.35 1.02 ± 0.85
(EPA) 12 2.91 ± 1.59*** 0.73 ± 0.49* 1.78 ± 1.48 0.71 ± 0.41
C22:5 n-3 0 0.39 ± 0.10 0.41 ± 0.10 0.43 ± 0.11 0.38 ± 0.09
(DPA) 12 0.57 ± 0.14*** 0.36 ± 0.11** 0.47 ± 0.18 0.31 ± 0.09*
C22:6 n-3 0 1.59 ± 0.56 1.50 ± 0.68 2.06 ± 0.91 1.64 ± 0.68
(DHA) 12 2.25 ± 0.69** 1.43 ± 0.72 1.92 ± 0.93 1.39 ± 0.63
AA/EPA 0 6.49 ± 3.71 8.24 ± 8.02 8.06 ± 8.31 7.76 ± 5.28
12 2.72 ± 2.12*** 17.6 ± 19.36 7.32 ± 6.55 9.23 ± 5.91
n-3 LC-PUFA 0 3.14 ± 1.37 2.95 ± 1.14 4.04 ± 2.24 3.04 ± 1.58
12 5.73 ± 2.35*** 2.52 ± 1.15* 4.17 ± 2.46 2.42 ± 1.07*
n-3 PUFA 0 3.82 ± 1.35 3.80 ± 1.05 4.55 ± 2.35 3.67 ± 1.89
12 6.17 ± 2.41** 2.97 ± 1.36** 4.64 ± 2.57 2.99 ± 1.25
n-6 PUFA 0 34.9 ± 2.97 36.6 ± 1.74 34.5 ± 4.02 36.0 ± 3.93
12 33.5 ± 3.74 37.6 ± 2.21* 34.6 ± 2.88 35.9 ± 3.62
n-6/n-3 0 10.5 ± 4.51 10.4 ± 3.57 9.70 ± 4.97 11.6 ± 4.61
12 6.39 ± 2.97** 15.1 ± 6.72* 10.7 ± 7.65 13.7 ± 4.99*
SFA 0 32.4 ± 1.67 32.1 ± 0.91 33.1 ± 2.32 32.7 ± 2.62
12 33.3 ± 2.12 33.1 ± 1.39* 33.7 ± 2.31 33.4 ± 3.22
MUFA 0 25.6 ± 2.16 24.5 ± 1.92 24.5 ± 2.95 24.2 ± 3.05
12 23.5 ± 2.56** 23.1 ± 1.63* 23.8 ± 2.25 24.6 ± 1.86
PUFA 0 39.2 ± 3.62 40.8 ± 2.11 39.5 ± 4.54 40.1 ± 4.41
12 40.2 ± 3.51 41.1 ± 2.58 39.6 ± 3.29 39.3 ± 3.92
CLA 0 0.34 ± 0.08 0.34 ± 0.08 0.31 ± 0.06 0.34 ± 0.08
12 0.42 ± 0.28 0.35 ± 0.19 0.27 ± 0.05 0.30 ± 0.08
a Fatty acids were separated gas chromatographically as corresponding fatty acid methyl esters (FAME).
b Data are expressed as mean ± SD of % total FAME.
* Significantly different compared to the start value (p ≤ 0.05); ** (p ≤ 0.01); *** (p ≤ 0.001).
LA linoleic acid, GLA g-linolenic acid, ALA a-linolenic acid, DGLA dihomo-g-linolenic acid, AA arachidonic acid, EPA eicosapentaenoic acid, DPA docosapentaenoic
acid, DHA docosahexaenoic acid, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, CLA conjugated fatty acids.
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Page 6 of 12Table 3 Fatty acid distribution in cholesteryl esters (CE) at baseline and after a 12 wk intake of the cap-sules
a,b
CE (% FAME) wks n-3 LC-PUFA
(group 1)
GLA
(group 2)
n-3 LC-PUFA + GLA
(group 3)
Control
(olive oil)
(group 4)
C16:0 0 11.2 ± 2.57 10.9 ± 1.22 11.1 ± 1.38 10.7 ± 1.26
12 11.3 ± 2.83 11.6 ± 0.99 12.7 ± 2.01** 10.3 ± 1.90
C16:1 0 3.21 ± 1.69 3.55 ± 2.66 3.06 ± 1.58 3.09 ± 1.21
12 3.48 ± 1.52 3.56 ± 2.47 2.92 ± 1.16 3.09 ± 1.25
C18:0 0 0.80 ± 0.46 0.75 ± 0.35 1.05 ± 1.54 0.70 ± 0.18
12 0.64 ± 0.15 0.57 ± 0.15 0.70 ± 0.15 0.86 ± 0.89
C18:1 n9 0 19.0 ± 2.65 19.1 ± 2.84 18.4 ± 2.28 18.5 ± 3.22
12 18.9 ± 2.53 18.4 ± 1.99 19.0 ± 2.12 18.3 ± 2.38
C18:2 n-6 0 50.9 ± 6.28 50.0 ± 6.56 49.7 ± 6.51 52.0 ± 4.80
(LA) 12 49.9 ± 5.39 47.6 ± 5.12* 49.5 ± 5.13 54.1 ± 4.41
C18:3 n-6 0 0.71 ± 0.26 0.58 ± 0.26 0.71 ± 0.49 0.59 ± 0.27
(GLA) 12 0.51 ± 0.25** 2.66 ± 0.60*** 1.26 ± 0.51* 0.55 ± 0.25
C18:3 n-3 0 0.69 ± 0.44 0.70 ± 0.38 0.43 ± 0.16 0.57 ± 0.26
(ALA) 12 0.37 ± 0.13* 0.46 ± 0.18 0.39 ± 0.13 0.53 ± 0.17
C20:3 n-6 0 0.55 ± 0.13 0.54 ± 0.13 0.55 ± 0.21 0.54 ± 0.12
(DGLA) 12 0.49 ± 0.15 1.22 ± 0.31*** 0.82 ± 0.15** 0.54 ± 0.08
C20:4 n-6 0 4.35 ± 1.34 4.36 ± 3.29 5.09 ± 2.36 3.77 ± 1.11
(AA) 12 4.24 ± 1.57 5.95 ± 1.98* 4.56 ± 1.86 3.92 ± 1.09
C20:5 n-3 0 0.63 ± 0.44 0.56 ± 0.55 0.98 ± 0.90 0.86 ± 1.03
(EPA) 12 1.95 ± 1.96* 0.45 ± 0.35 0.94 ± 0.85 0.51 ± 0.42
C22:5 n-3 0 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.01
(DPA) 12 0.03 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01
C22:6 n-3 0 0.29 ± 0.17 0.24 ± 0.16 0.36 ± 0.19 0.30 ± 0.21
(DHA) 12 0.36 ± 0.25 0.23 ± 0.16 0.25 ± 0.15 0.27 ± 0.23
AA/EPA 0 9.61 ± 5.57 45.8 ± 90.9 22.7 ± 43.7 10.5 ± 9.13
12 9.13 ± 16.0 23.1 ± 20.2 19.1 ± 36.1 13.4 ± 11.3
n-3 LC-PUFA 0 0.94 ± 0.59 0.83 ± 0.67 1.37 ± 1.09 1.18 ± 1.23
12 2.34 ± 2.20* 0.70 ± 0.49 1.21 ± 0.98 0.79 ± 0.65
n-3 PUFA 0 1.65 ± 0.71 1.54 ± 0.89 1.81 ± 1.22 1.77 ± 1.43
12 2.73 ± 2.31 1.17 ± 0.65 1.62 ± 1.06 1.33 ± 0.76
n-6 PUFA 0 56.7 ± 6.02 55.7 ± 7.55 56.1 ± 4.55 57.0 ± 4.87
12 55.3 ± 5.38 57.5 ± 5.78 56.3 ± 4.70 59.2 ± 4.19
n-6/n-3 0 41.2 ± 18.4 49.2 ± 34.2 57.0 ± 67.2 50.7 ± 36.4
12 45.9 ± 54.9 62.0 ± 30.0 65.2 ± 78.0 56.9 ± 29.1
SFA 0 14.3 ± 3.30 14.2 ± 1.65 14.8 ± 2.88 14.2 ± 2.38
12 13.4 ± 4.51 14.4 ± 1.23 15.5 ± 2.49 13.4 ± 2.56
MUFA 0 24.1 ± 4.12 24.6 ± 5.34 23.4 ± 3.60 23.7 ± 4.07
12 24.4 ± 3.92 23.8 ± 4.56 24.0 ± 2.90 23.3 ± 3.37
PUFA 0 58.5 ± 6.34 57.5 ± 7.88 58.2 ± 4.68 59.0 ± 5.55
12 58.2 ± 4.84 58.8 ± 6.01 58.1 ± 4.46 60.7 ± 4.37
CLA 0 0.19 ± 0.11 0.23 ± 0.13 0.19 ± 0.06 0.22 ± 0.09
12 0.20 ± 0.11 0.14 ± 0.05 0.17 ± 0.07 0.18 ± 0.07
a Fatty acids were separated gas chromatographically as corresponding fatty acid methyl esters (FAME).
b Data are expressed as mean ± SD of % total FAME.
* Significantly different compared to the start value (p ≤ 0.05); ** (p ≤ 0.01); *** (p ≤ 0.001).
LA linoleic acid, GLA g-linolenic acid, ALA a-linolenic acid, DGLA dihomo-g-linolenic acid, AA arachidonic acid, EPA eicosapentaenoic acid, DPA docosapentaenoic
acid, DHA docosahexaenoic acid, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, CLA conjugated fatty acids.
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Page 7 of 12Table 4 Fatty acid distribution in erythrocyte membranes (EM) at baseline and after a 12 wk intake of the capsules
a,b
EM (% FAME) wks n-3 LC-PUFA
(group 1)
GLA
(group 2)
n-3 LC-PUFA + GLA
(group 3)
Control (olive oil)
(group 4)
C16:0 0 21.5 ± 2.42 19.9 ± 6.94 24.5 ± 6.69 21.9 ± 1.63
12 22.8 ± 1.45* 22.7 ± 2.44 21.6 ± 3.26 21.9 ± 2.46
C16:1 0 0.30 ± 0.05 0.30 ± 0.08 0.35 ± 0.16 0.36 ± 0.18
12 0.31 ± 0.11 0.39 ± 0.18 0.44 ± 0.44 0.39 ± 0.19
C18:0 0 15.3 ± 0.92 15.4 ± 1.14 15.1 ± 1.74 15.7 ± 1.23
12 15.3 ± 1.75 14.6 ± 2.42 14.7 ± 2.56 15.4 ± 1.11
C18:1 n9 0 14.6 ± 1.78 14.5 ± 1.41 14.1 ± 1.55 13.9 ± 1.36
12 13.5 ± 0.99* 13.1 ± 1.20 13.3 ± 1.92 13.9 ± 1.41
C18:2 n-6 0 7.77 ± 0.79 8.09 ± 0.83 7.14 ± 1.66 8.13 ± 1.23
(LA) 12 7.18 ± 0.98* 7.73 ± 1.39 7.27 ± 1.55 8.14 ± 0.88
C18:3 n-6 0 0.06 ± 0.02 0.05 ± 0.01 0.04 ± 0.02 0.05 ± 0.01
(GLA) 12 0.04 ± 0.02*** 0.15 ± 0.05*** 0.07 ± 0.03* 0.04 ± 0.01
C18:3 n-3 0 0.13 ± 0.07 0.15 ± 0.05 0.12 ± 0.07 0.12 ± 0.05
(ALA) 12 0.08 ± 0.03** 0.09 ± 0.03* 0.10 ± 0.06 0.10 ± 0.03
C20:3 n-6 0 1.21 ± 0.28 1.23 ± 0.16 0.99 ± 0.29 1.24 ± 0.18
(DGLA) 12 0.95 ± 0.20*** 2.12 ± 0.51*** 1.37 ± 0.30** 1.25 ± 0.16
C20:4 n-6 0 12.96 ± 2.44 12.6 ± 1.80 11.27 ± 3.82 12.3 ± 1.73
(AA) 12 11.08 ± 2.03*** 12.0 ± 1.91 10.40 ± 3.26 11.6 ± 2.39
C20:5 n-3 0 0.59 ± 0.24 0.71 ± 0.44 0.62 ± 0.35 0.68 ± 0.36
(EPA) 12 2.00 ± 0.87*** 0.53 ± 0.34 1.09 ± 0.69* 0.55 ± 0.33
C22:5 n-3 0 1.46 ± 0.26 1.54 ± 0.32 1.23 ± 0.51 1.45 ± 0.33
(DPA) 12 2.17 ± 0.43*** 1.38 ± 0.54 1.56 ± 0.59 1.36 ± 0.41
C22:6 n-3 0 2.51 ± 0.61 2.68 ± 1.12 2.51 ± 1.22 2.65 ± 0.78
(DHA) 12 3.47 ± 0.89** 2.70 ± 1.48 2.65 ± 1.16 2.47 ± 0.94
AA/EPA 0 25.1 ± 10.1 28.4 ± 25.6 35.6 ± 49.0 24.2 ± 14.5
12 7.17 ± 4.66*** 43.8 ± 48.4 16.0 ± 15.3 27.4 ± 13.7
n-3 LC-PUFA 0 4.56 ± 0.94 4.93 ± 1.73 4.36 ± 1.97 4.77 ± 1.28
12 7.64 ± 2.01*** 4.61 ± 2.26 5.29 ± 2.17 4.38 ± 1.60
n-3 index 0 3.10 ± 0.82 3.39 ± 1.48 3.13 ± 1.48 3.32 ± 1.02
12 5.47 ± 1.66*** 3.23 ± 1.81 3.73 ± 1.63 3.02 ± 1.23
n-3 PUFA 0 4.77 ± 0.93 5.17 ± 1.61 4.56 ± 1.88 4.91 ± 1.30
12 7.76 ± 1.99*** 4.73 ± 2.26 5.43 ± 2.17 4.52 ± 1.56
n-6 PUFA 0 22.2 ± 2.22 22.1 ± 1.71 19.6 ± 5.54 21.9 ± 2.32
12 19.3 ± 2.19*** 22.1 ± 2.20 19.3 ± 4.13 21.2 ± 2.65
n-6/n-3 0 4.79 ± 0.90 4.69 ± 1.61 4.95 ± 2.34 4.74 ± 1.34
12 2.70 ± 0.96*** 6.29 ± 4.16 4.18 ± 1.95 5.16 ± 1.56
SFA 0 40.5 ± 3.04 39.1 ± 7.63 45.1 ± 9.16 41.4 ± 2.97
12 42.3 ± 2.97* 42.2 ± 6.13 41.5 ± 5.21 42.3 ± 5.63
MUFA 0 20.8 ± 1.98 20.9 ± 1.24 20.6 ± 1.14 20.9 ± 1.30
12 20.3 ± 0.67 19.8 ± 1.02* 20.2 ± 1.67 20.9 ± 1.34
PUFA 0 28.2 ± 2.63 28.4 ± 2.38 25.4 ± 7.10 28.0 ± 2.59
12 28.3 ± 2.05 28.0 ± 4.07 26.0 ± 5.42 26.8 ± 3.58
CLA 0 0.86 ± 0.37 0.71 ± 0.24 0.78 ± 0.28 0.73 ± 0.23
12 0.71 ± 0.21 0.62 ± 0.16 0.72 ± 0.26 0.71 ± 0.17
a Fatty acids were separated gas chromatographically as corresponding fatty acid methyl esters (FAME).
b Data are expressed as mean ± SD of % total FAME.
* Significantly different compared to the start value (p ≤ 0.05); ** (p ≤ 0.01); *** (p ≤ 0.001).
LA linoleic acid, GLA g-linolenic acid, ALA a-linolenic acid, DGLA dihomo-g-linolenic acid, AA arachidonic acid, EPA eicosapentaenoic acid, DPA docosapentaenoic
acid, DHA docosahexaenoic acid, SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids, CLA conjugated fatty acids.
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Page 8 of 12n-3 LC-PUFA/d in group 4, 0.4 g n-3 LC-PUFA/d in
group 2, and 0.6 g n-3 LC-PUFA/d in groups 1 and 3
(Table 5). The predominant types of fish consumed
included salmon, redfish, tuna, herring and trout.
Correlation analyses
Correlation analyses of the disease activity parameters
(DAS28, VAS) and chosen FA (AA, EPA, DHA, AA/
EPA, GLA, DGLA, DGLA/AA) in PL, CE, and EM were
conducted using baseline values. One asterisk indicates
a significance of p ≤ 0.05, while two asterisks indicate a
significance of p ≤ 0.01.
There was a significant positive correlation between
DAS28 and AA (r = 0.342*) and DGLA (r = 0.348*) in
CE. Further, there was a negative association between
EPA in EM and VAS (r = -0.323*) and between DHA in
EM and DAS (r = - 0.361*). The ratio of AA/EPA in
EM correlated significantly with VAS (r = 0.343*) and
there was an association between VAS and DAS28 (r =
0.419**). Additionally, there were strong correlations
between GLA (r = 0.375*), DGLA (r = 0.486**), AA (r =
0.730**), EPA (r = 0.463**), DHA (r = 0.552**), and
DGLA/AA ratio (r = 0.417**) in PL and these FAs or
ratios in CE; between AA (r = 0.395**), EPA (r =
0.521**), DHA (r = 0.447**), AA/EPA (r = 0.899**), and
DGLA/AA (r = 0.474**) in PL and these FAs or ratios
in EM. The correlation analyses also showed a strong
relationship between GLA - DGLA (**), AA - GLA (*),
and AA - DGLA (**) concentrations in PL, CE, and EM.
In contrast, there was no significant correlation between
proportions of EPA and AA, EPA and DAS28, or DHA
and AA concentrations.
Discussion
Red blood cell membranes are biomarkers of medium-
term FA intake as they reflect the intake ac-cumulated
over the lifespan of erythrocytes (approx. 120d). Fatty
acids, found in plasma lipids (e.g., CE) reflect food con-
sumption over the last few days [21-23]. In the present
study, concentrations of supplemented PUFA increased
Table 5 Dietary intake at baseline and after 12 wks dietary intervention
a
Nutrients
(51 ≤ 65 y)
D-A-C-H wks n-3 LC-PUFA
(group 1)
GLA
(group 2)
n-3 LC-PUFA + GLA
(group 3)
Control (olive oil)
(group 4)
Energy 8500 (f) 0 7823 ± 2064 8893 ± 2821 9021 ± 3165 8317 ± 2038
(KJ) 10500 (m) 12 7246 ± 1644 7724 ± 3130 7937 ± 2645 7506 ± 2569
Carbohydrates 225 (f) 0 217.6 ± 80.5 256.5 ± 80.6 251 ± 80.1 182.9 ± 82.2
g/d 288 (m) 12 178.3 ± 52.5 206.5 ± 102.8* 205 ± 49.3 206.9 ± 74.0
Protein 46 (f) 0 78.5 ± 23.1 79.4 ± 25.0 92.1 ± 28.3 119.4 ± 88.7
g/d 58 (m) 12 100.1 ± 93.4 75.9 ± 31.1 83.1 ± 46.5 69.5 ± 23.0
Fat 60 (f) 0 68.0 ± 19.4 76.4 ± 42.8 77.5 ± 37.3 78.3 ± 28.5
g/d 77 (m) 12 63.7 ± 21.7 67.7 ± 36.2 71.5 ± 31.1 68.6 ± 28.9
Dietary fiber 25 0 27.2 ± 8.86 28.5 ± 9.90 35.1 ± 13.1 19.9 ± 6.70
g/d 12 23.2 ± 9.14 23.6 ± 15.9 27 ± 8.63* 23.6 ± 11.3
Alcohol 0 6.42 ± 10.2 8.96 ± 11.0 7.7 ± 6.67 7.85 ± 8.50
g/d 12 4.28 ± 3.50 11.5 ± 13.9 10.5 ± 12.7 6.49 ± 5.61
SFA < 20 0 25.0 ± 8.51 27.1 ± 13.3 26.1 ± 14.1 26.3 ± 10.2
g/d < 26 12 25.0 ± 11.0 26.0 ± 13.1 23.4 ± 8.94 24.8 ± 7.98
MUFA < 20 0 24.0 ± 7.96 25.2 ± 16.8 27.4 ± 14.8 28.1 ± 11.5
g/d < 26 12 21.5 ± 7.67 25.0 ± 13.7 26.8 ± 11.4 24.4 ± 12.5
PUFA 14 - 20 0 11.2 ± 3.63 12.8 ± 6.30 13.1 ± 6.03 11.8 ± 5.54
g/d 18 - 26 12 10.4 ± 5.61 10.7 ± 7.51 12 ± 5.14 11.1 ± 7.67
Ca 1000 0 999 ± 328 896 ± 401 999 ± 359 879 ± 380
mg/d 12 1028 ± 269 888 ± 399 841 ± 382 1008 ± 417
Intake of fish an fish products
no intake
(%)
23 25 15 30
1 - 2 portions/wk (%) 36 42 35 40
> 2 portions/wk (%) 41 33 50 30
Intake of n-3 LC-PUFA 0.57 ± 0.75 0.37 ± 0.41 0.64 ± 1.00 0.26 ± 0.36
a Data are expressed as mean ± SD.
* Significantly different compared to the start value (p ≤ 0.05).
SFA saturated fatty acids, MUFA monounsaturated fatty acids, PUFA polyunsaturated fatty acids.
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Page 9 of 12in the analysed tissues (PL, CE, EM) in proportion to
the supplemented dosages (Table 2, 3, 4), indicating a
good compliance and a high bioavailability of the sup-
plemented PUFA. An assessment of the resulting
changes in PL, CE, and EM in response to the supple-
mentation (group 1-4) indicated that PL and EM are
reliable biomarkers for PUFA intake (Table 2, 4). The
alterations in CE cannot be clearly interpreted due to
the comparably high standard deviations within the
groups (Table 3), possibly resulting from the methods
used for sample preparation including a double TLC
purification.
The consumption of 3 g n-3 LC-PUFA resulted in a
high increase in EPA and DHA proportions, in turn,
leading to a decrease of AA concentrations in EM as well
as the AA/EPA ratio in PL, CE, and EM (Table 2, 3, 4).
In RA, various pro-inflammatory metabolites of AA, such
as LTB4 and PGE2 contribute to tissue destruction and
pain [1]. The AA concentration of the membranes is an
important regulatory step in the synthesis of these pros-
tanoids and LTs. In effect, the AA/EPA ratio in cell lipids
determines the degree of competitive eicosanoid inhibi-
tion. The observed outcome on the ratio of these eicosa-
noid precursory FAs in EM indicated for a reduction in
the production of PGs and LTs from AA. Additionally,
the increase of EPA and DHA could promote the pro-
duction of proresolving mediators like resolvins, protec-
tins, and maresins. Following from this, a significant
reduction of disease activity parameters (DAS28, VAS
scale) was observed in this group. Previous intervention
trials with fish oil in patients with RA have shown a
decrease in LTB4 as the most prominent feature of lipox-
ygenase inhibition due to n-3 LC-PUFA [24-26]. Recent
RCT’sa sw e l la st h er e s u l t so ft h ep r e s e n tt r i a ls u g g e s t
that daily fish oil supplementation at dosages of around
3 g n-3 LC-PUFA for approximately 12 wks are sufficient
to effectuate a clinical benefit in patients with RA
[25-35]. There is also increased evidence that the restric-
tion of AA intake enhanced the anti-inflammatory effects
of n-3 LC-PUFA intervention in RA patients [4,24,34,36].
Additionally, the AA/EPA ratio and the n-3 FA index
which represent highly discriminative risk factors for
sudden cardiac death [17,37] were significantly improved
due to consumption of 3 g n-3 LC-PUFA (group 1;
Table 4). This is an added benefit because the CV mor-
tality is strongly elevated in patients with RA [38,39].
The administration of GLA leads to a dose-dependen-
dent increase of GLA and of its elongation metabolite
DGLA in EM (Table 4). The disease activity parameters
were also diminished in this group. The increase of DGLA
concentration in the membrane indicates for blocking the
metabolism of AA and changing the balance of lipid med-
iators towards the production of less potent 1-series PGs
via the cyclooxygenase (COX) pathway and via the 15-
lipoxygenase (15-LOX) pathway to 15(S)-hydroxyeicosa-
trienoic acid (15-HETrE; [40]). Because DGLA competes
with AA for COX and 5-LOX, the production of 2-series
PGs and 4-series LTs from AA is reduced [41]. PGE1 has
a negative feedback role in chronic inflammation, initially
aiding in the development of the cardinal signs of inflam-
mation but later suppressing inflammation. PGE1 sup-
pressed the immune response by increasing intracellular
cyclic AMP (cAMP) in polymorphonuclear leukocytes
resulting in a reduction in the release of lysosomal
enzymes, polymorphonuclear leukocyte chemotaxis,
adherence of leukocytes in the blood vessels, and PGE1
regulates IL-6 signal transduction [42-45].
Eskimos living on a traditional diet rarely suffer from
coronary heart disease (CHD), psoriasis, asthma, and
RA. It is hypothesized that not only the high dietary
intake of EPA, but also the comparably low plasma con-
centrations of AA as well as the high plasma concentra-
tions of DGLA are responsible for the low prevalence of
these diseases [46]. The combination of n-3 LC-PUFA
and GLA tested in the present study (group 3) had no
significant effect on disease activity parameters (DAS28,
VAS scale; [18,19,47]). However, because of the high
initial AA concentrations due to the Western diet, it is
almost impossible for us to reproduce the very low
Eskimo AA concentra-tions which result from a lifetime
of genetically reduced AA production.
GLA is a potential precursor of AA via its metabolism
by elongase along with d5-desaturase activities [48].
Accordingly, a marked increase in the quantity of AA in
PL and CE due to supplementation of 3 g GLA/d was
demonstrated in the present trial (group 2; Table 2, 3),
indicating for the potential of dietary GLA to be elongated
to DGLA and subsequently desaturated to AA. A similar
rise was not seen in EM which is indicative of a temporary
accumulation of AA (Table 4). Interestingly, there was no
increase of AA in PL, CE and EM for supplementation
with combined n-3-LC-PUFA + GLA/d (group 3; Table 2,
3, 4). Concluding from this, the addition of EPA due to
GLA intervention attenuates the conversion of DGLA to
AA by blocking d5-desaturase activity. Further, compari-
son of variations in DGLA concentrations in groups 2 and
3 showed a strong dose-dependent increase of DGLA in
CE and EM (Table 3, 4).
Olive oil has classically been used as a placebo in stu-
dies investigating the effects of fish oil in pa-tients with
RA. In the present trial, ingesting of 3 g olive oil revealed
a trend towards a decrease of DAS28 [47]. A low
improvement of disease activity was also observed in
some earlier studies [25,34,49] because olive oil contains
minor components with antiinflammatory potential, e.g.,
squalene, plant sterols, tocopherols, and polyphenols
[50-52]. These data suggest that olive oil itself could have
beneficial effects in RA/PA.
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The concentrations of the supplemented PUFA increased
in the analysed tissues (PL, CE, EM) in proportion to the
supplemented dosages indicating a good compliance as
well as a high bioavailability of the supplemented PUFA.
The intake of capsules enriched with n-3 LC-PUFA or
GLA (3 g/d) resulted in an increased incorporation of the
eicosanoid precursor FAs (EPA, DHA, DGLA) in plasma
lipids and cell membranes as well as a subsequent
improvement in clinical status of patients with chronic
inflammatory diseases. These changes on FA distribution
are indicative for a reduction in the production of inflam-
matory eicosanoids from AA. In addition, the intake of
n-3 LC-PUFA improved cardiovascular risk factors, e.g.,
AA/EPA ratio and n-3 FA index.
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